Search - tctmd.com

Displaying 121 - 140 of 288

Sort: Relevancy | Date

News Daily News

Plaque Burden, Not Coronary Stenosis, Linked to Future Events in Stable CAD

Michael O'Riordan

December 07, 2020

News Conference News AHA 2020

No Doctor? No Problem: Remote, Pharmacist-Led Intervention Cuts CVD Risk

Michael O'Riordan

November 19, 2020

News Conference News AHA 2020

Both Statins and Placebos Produce ‘Very Real’ Side Effects: SAMSON

Michael O'Riordan

November 15, 2020

News Conference News AHA 2020

Statin Benefits Confirmed in Elderly, Along With Harmful Effects of High Cholesterol

Michael O'Riordan

November 12, 2020

News Conference News EAS 2020

Inclisiran Effective Across FH Genotypes, as Well as in Primary Prevention

Michael O'Riordan

October 08, 2020

News Conference News EAS 2020

Lp(a) and LPA Genetic Risk Score Both Predict Incident ASCVD: UK Biobank

Michael O'Riordan

October 07, 2020

News Daily News

Increased Lifetime Exposure to High LDL Cholesterol Predicts ASCVD

Michael O'Riordan

September 22, 2020

News Daily News

LDL Cholesterol Control Post-PCI Is Low and Linked to Worse Outcomes

Yael L. Maxwell

September 14, 2020

News Daily News

Young Patients With Premature ASCVD Less Likely to Receive Statins, Aspirin

Michael O'Riordan

August 25, 2020

News Daily News

Inflammation Plays Into the ASCVD Risk Associated With Lp(a): ACCELERATE

Michael O'Riordan

July 08, 2020

News Daily News

Coronary Calcium-Guided Statin Strategy Cost-effective in African-Americans

Michael O'Riordan

May 15, 2020

News Daily News

FOURIER Surveys Reassure About Cognitive Safety of Evolocumab

Todd Neale

May 06, 2020

News Daily News

Different Markers of Dyslipidemia Could Help Fine-tune CVD Prevention

Yael L. Maxwell

April 28, 2020

News Conference News ACC 2020

Alirocumab Successfully Reduces LDL Cholesterol in Homozygous FH: ODYSSEY HoFH

Yael L. Maxwell

April 06, 2020

News Conference News ACC 2020

Icosapent Ethyl’s CV Benefit Closely Tied to Serum EPA Levels: REDUCE-IT

Todd Neale

April 02, 2020

News Conference News ACC 2020

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

Michael O'Riordan

April 02, 2020

Hope for these hard-to-treat patients: more than half saw ≥ 50% decrease at 24 weeks, regardless of LDL receptor function.

News Conference News ACC 2020

Evinacumab Cuts LDL Cholesterol in Homozygous FH

Yael L. Maxwell

April 01, 2020

News Daily News

Long-term Evolocumab Safe, Effective for Familial Hypercholesterolemia Treatment

Yael L. Maxwell

February 12, 2020

News Daily News

Free Pass? Lifestyle Slips for Patients Starting Certain Preventive Meds

Michael O'Riordan

February 06, 2020

News Daily News

Earlier, Longer Interventions Proposed for Optimal Population LDL Cholesterol

Yael L. Maxwell

January 28, 2020

Advertisement

Plaque Burden, Not Coronary Stenosis, Linked to Future Events in Stable CAD

No Doctor? No Problem: Remote, Pharmacist-Led Intervention Cuts CVD Risk

Both Statins and Placebos Produce ‘Very Real’ Side Effects: SAMSON

Statin Benefits Confirmed in Elderly, Along With Harmful Effects of High Cholesterol

Inclisiran Effective Across FH Genotypes, as Well as in Primary Prevention

Lp(a) and LPA Genetic Risk Score Both Predict Incident ASCVD: UK Biobank

Increased Lifetime Exposure to High LDL Cholesterol Predicts ASCVD

LDL Cholesterol Control Post-PCI Is Low and Linked to Worse Outcomes

Young Patients With Premature ASCVD Less Likely to Receive Statins, Aspirin

Inflammation Plays Into the ASCVD Risk Associated With Lp(a): ACCELERATE

Coronary Calcium-Guided Statin Strategy Cost-effective in African-Americans

FOURIER Surveys Reassure About Cognitive Safety of Evolocumab

Different Markers of Dyslipidemia Could Help Fine-tune CVD Prevention

Alirocumab Successfully Reduces LDL Cholesterol in Homozygous FH: ODYSSEY HoFH

Icosapent Ethyl’s CV Benefit Closely Tied to Serum EPA Levels: REDUCE-IT

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

Evinacumab Cuts LDL Cholesterol in Homozygous FH

Long-term Evolocumab Safe, Effective for Familial Hypercholesterolemia Treatment

Free Pass? Lifestyle Slips for Patients Starting Certain Preventive Meds

Earlier, Longer Interventions Proposed for Optimal Population LDL Cholesterol

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content